Prosidion acquires Probiodrug's DP-IV platform and assets
OSI Pharmaceuticals' majority owned subsidiary Prosidion Ltd. (small-molecule therapeutics for diabetes and obesity) is purchasing Probiodrug AG's dipeptidyl peptidase IV (DP-IV) technology platform and related intellectual property for €29mm ($35mm) in cash.
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.